Comprehensive analysis of pan‐cancer reveals potential of ASF1B as a prognostic and immunological biomarker

Hu, Xinyao; Zhu, Hua; Zhang, Xiaoyu; He, Xueling; Xu, Ximing

doi:10.1002/cam4.4203

Cited by 32 publications

(32 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, an increasing number of studies have found a correlation between cancer progression and tumor immune infiltration ( 30 , 31 ). Through public data mining, we also found a certain correlation between the expression of ASF1B and the immune infiltration of HCC, which is consistent with the conclusions of current reports ( 28 , 29 ). But the specific experiments need to be further verified.…”

Section: Discussionsupporting

confidence: 90%

“…In this research, we used bioinformatics and multiple databases to comprehensively analyze the expression of ASF1B in pan-cancer, and found that ASF1B was abnormally expressed in most cancers, including liver cancer, which is consistent with current literature reports (27)(28)(29). In order to explore the relationship between ASF1B and HCC in detail, RNA-seq data and corresponding clinical data of HCC in TCGA were analyzed separately.…”

Section: Discussionsupporting

confidence: 65%

See 1 more Smart Citation

ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma

Ouyang

Zhao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with high morbidity and mortality. Therefore, it is very important to find potential biomarkers that can effectively predict the prognosis and progression of HCC. Recent studies have shown that anti-silencing function 1B (ASF1B) may be a new proliferative marker for tumor diagnosis and prognosis. However, the expression and function of ASF1B in hepatocellular carcinoma remain to be determined. In this study, integrated analysis of the Cancer Genome Atlas (TCGA), genotypic tissue expression (GTEx), and Gene Expression Omnibus (GEO) databases revealed that ASF1B was highly expressed in HCC. Kaplan-Meier survival curve showed that elevated ASF1B expression was associated with poor survival in patients with liver cancer. Correlation analysis of immune infiltration suggested that ASF1B expression was significantly correlated with immune cell infiltration in HCC patients. Gene set enrichment analysis (GSEA) indicated that ASF1B regulated the cell cycle, DNA Replication and oocyte meiosis signaling. Our experiments confirmed that ASF1B was highly expressed in HCC tissues and HCC cell lines. Silence of ASF1B inhibited hepatocellular carcinoma cell growth in vitro. Furthermore, ASF1B deficiency induced apoptosis and cell cycle arrest. Mechanistically, ASF1B knockdown reduced the expression of proliferating cell nuclear antigen (PCNA), cyclinB1, cyclinE2 and CDK9.Moreover, ASF1B interacted with CDK9 in HCC cells. Taken together, these results suggest that the oncogenic gene ASF1B could be a target for inhibiting hepatocellular carcinoma cell growth.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 65%

ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma

Ouyang

Zhao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In addition, several studies have underlined the important prognostic impact of ASF1B on a variety of cancers ( Corpet et al, 2011 ; Chen Z. et al, 2021 ; Feng et al, 2021 ). Another exciting finding was that ASF1B could regulate immune infiltration through affecting immune-related genes and pathways such as antigen processing and presentation and natural killer cell-mediated cytotoxicity ( Hu et al, 2021 ; Zhan et al, 2021 ), conferring its strong hints on potential immunotherapeutic target for several malignancies. The both overall and disease free survival analysis also demonstrated that the high expression of ASF1B was associated with high risk ( Figures 4C , 5C ), suggesting it serving as a tumor promoter in pancreatic adenocarcinoma.…”

Section: Resultsmentioning

confidence: 99%

Identification of Survival-Associated Hub Genes in Pancreatic Adenocarcinoma Based on WGCNA

Huang¹,

Ye²,

Wang³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Pancreatic adenocarcinoma is one of the leading causes of cancer-related death worldwide. Since little clinical symptoms were shown in the early period of pancreatic adenocarcinoma, most patients were found to carry metastases when diagnosis. The lack of effective diagnosis biomarkers and therapeutic targets makes pancreatic adenocarcinoma difficult to screen and cure. The fundamental problem is we know very little about the regulatory mechanisms during carcinogenesis. Here, we employed weighted gene co-expression network analysis (WGCNA) to build gene interaction network using expression profile of pancreatic adenocarcinoma from The Cancer Genome Atlas (TCGA). STRING was used for the construction and visualization of biological networks. A total of 22 modules were detected in the network, among which yellow and pink modules showed the most significant associations with pancreatic adenocarcinoma. Dozens of new genes including PKMYT1, WDHD1, ASF1B, and RAD18 were identified. Further survival analysis yielded their valuable effects on the diagnosis and treatment of pancreatic adenocarcinoma. Our study pioneered network-based algorithm in the application of tumor etiology and discovered several promising regulators for pancreatic adenocarcinoma detection and therapy.

show abstract

“…Immunotherapy for tumors has recently emerged as a new approach to oncology treatment, specifically immune checkpoint blockade (ICB) therapy [ 4 ]. The emergence and refinement of gene expression databases have enabled explorations of new immunotherapeutic targets through pan-cancer analysis of the expression of particular gene and assessments of its relevance to patients' prognoses and potential mechanisms [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…The infiltration levels of TIIC in TME also impact on the prognoses of cancers. For example, high levels of B, CD4+, and dendritic cells infiltration are associated with a better outcome in thymomas, which may be partially regulated by ASF1B [ 6 ]. Lower grade glioma (LGG) patients with high TUBA1C expression may have a better response to ICB [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

The Hypoxia-Related Gene COL5A1 Is a Prognostic and Immunological Biomarker for Multiple Human Tumors

Zhu

Shan

et al. 2022

Oxidative Medicine and Cellular Longevity

Self Cite

View full text Add to dashboard Cite

Background. Collagen type V alpha 1 chain (COL5A1) is a hypoxia-related gene (a collagen family protein) and participates in the formation of the extracellular matrix. Although some evidence supports a significant role for COL5A1 in the progression of several cancers, a pan-cancer analysis of COL5A1 is not currently available. Herein, we aimed to assess the prognostic value of COL5A1 in 33 human cancers and to investigate its underlying immunological function. Methods. Through multiple bioinformatics methods, we analyzed the data from Oncomine, TCGA, CCLE, HPA, DNMIVD, and cBioPortal database to explore the potential underlying carcinogenic effect of COL5A1, including the relevance of COL5A1 to the outcome, DNA methylation, tumor microenvironment, immune cells infiltration, and drug sensitivity in 33 human cancers. The effects of COL5A1 on glioma cell proliferation, migration, and invasion were verified in cellular experiments. Results. Our findings indicated that COL5A1 was expressed at high levels in 13 cancers and was negatively related to the prognosis of 11 cancers. Additionally, COL5A1 was coexpressed with genes encoding the major histocompatibility complex, immune activators, immune suppressors, chemokines, chemokine receptors, mismatch repair genes, and immune checkpoints. We also identified different roles for COL5A1 in the immunocyte infiltration in different cancers. The correlation between COL5A1 and drug sensitivity was found in several cancers. COL5A1 potentially influenced the tumor progression through immune-related pathways, negative regulation of immune system processes, chemokine signaling pathways, JAK-STAT pathways, T cell receptor pathways, lymphocyte migration, and antigen processing and presentation, among other processes. Conclusions. Based on our study, COL5A1 may be employed as a prognostic marker in different malignancies because of its impact on tumorigenesis and immune cell infiltration and have implications for cancer immune checkpoint inhibitors and chemotherapy.

show abstract

Comprehensive analysis of pan‐cancer reveals potential of ASF1B as a prognostic and immunological biomarker

Cited by 32 publications

References 33 publications

ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma

ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma

Identification of Survival-Associated Hub Genes in Pancreatic Adenocarcinoma Based on WGCNA

The Hypoxia-Related Gene COL5A1 Is a Prognostic and Immunological Biomarker for Multiple Human Tumors

Contact Info

Product

Resources

About